Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit reported statistically significant Phase III overall survival results for ivonescimab plus chemotherapy in first-line squamous NSCLC, with a hazard ratio of 0.66, implying a 34% reduction in risk of death versus tislelizumab plus chemotherapy. The 24-month OS rate was 64.7% versus 48.6%, and safety remained manageable with no new signals. The data were simultaneously published in The Lancet and add further validation to Summit's ivonescimab pipeline and partnership with Akeso.

Analysis

This is a material de-risking event for SMMT because it converts ivonescimab from a “PFS story” into a plausible frontline OS asset in a head-to-head against the current standard-of-care class. The market should start discounting a higher probability that the drug is not just additive to checkpoint therapy but competitively differentiated versus PD-1-based chemo regimens, which is the key hurdle for pricing power and eventual share in first-line NSCLC.

The second-order effect is on the broader IO/VEGF strategy set: if ivonescimab can show OS with manageable bleeding risk in squamous disease, it weakens the long-held assumption that VEGF + IO combinations need to be split into separate antibodies and still remain commercially viable. That is negative for any developer trying to justify a conventional anti-VEGF plus PD-(L)1 regimen in squamous tumors, and it increases the optionality value of Summit’s remaining readouts because success in one histology raises the base rate for adjacent settings.

The key risk is that this is still an interim, China-only dataset run by the partner, so the main debate will be translational durability and external validity rather than the headline HR. Investors will likely overreact in the near term, but the more important catalyst path is whether this meaningfully improves the odds of the U.S. BLA / FDA review and whether later global studies can replicate the effect; if either gets wobbly, the multiple can compress fast because the stock is now priced on franchise potential, not just trial success.

Consensus is probably missing how asymmetric the readthrough is for valuation: the downside from failure in later studies is now less about “no drug” and more about “best-in-class regional oncology asset,” while the upside is a platform rerating if global data line up. That makes the event positive but not cleanly one-way; after a sharp gap up, the better trade may be to own strength via calls rather than chase common equity outright.

Key Decisions for Investors

• Long SMMT into the June 1 conference call, but prefer call spreads over stock: buy 3-6 month calls and sell 30-50% higher strikes to capture rerating while capping gap-risk if management guidance disappoints.
• Trim short-biotech baskets that include late-stage NSCLC exposure; this readthrough raises the bar for peers pursuing conventional PD-1 + chemo combinations, especially names with no differentiated mechanism.
• Consider a relative-value long SMMT / short a basket of IO peers with upcoming frontline lung data over the next 1-2 quarters; the asymmetry favors SMMT as the market re-prices probability of OS superiority.
• If SMMT gaps >15-20% on the headline, fade some common equity into strength and roll into longer-dated options; the near-term catalyst is strong, but the next true inflection is FDA/BLA and global replication over months, not days.